Clinical Features Of Extremity Or Trunk Sarcomas In Patients Aged 80 Or Older.

e22546 Background: Because of the dramatic increase in life expectancy in recent decades, the treatment of malignant neoplasm in elderly people has become the focus of attention. However, little is known about soft-tissue sarcomas in the elderly population. Methods: Subjects were retrieved from the institutional database. Inclusion criteria were (1) no metastasis at first presentation, (2) extremity or trunk wall sarcomas, (3) surgery at our institution in 1996–2012, and (4) ≥ 2 years of follow-up for non-event patients. Patients referred after unplanned excision followed by re-excision at our institution were included, but intermediate malignancy tumors, such as well-differentiated liposarcoma and solitary fibrous tumor, were not included. Patient information including age, gender, pathological diagnosis, FNCLCC grade, size, depth, surgical margin status, was collected. Patient characteristics and clinical outcomes, local-recurrence-free survival (LRFS), disease-specific survival (DSS), and overall survival (OS), were compared between patients aged < 80 and ≥ 80. A P-value of < 0.05 was regarded as statistically significant. Results: A total of 369 cases were included in this study. Thirty-six patients (10%) were aged ≥ 80. The older group ( ≥ 80) was significantly higher FNCLCC grade and had a significantly lower adjuvant chemotherapy administration rate. The margin status was comparable between the two groups (Table). LRFS, DSS, and OS were compared among grade 2 or 3 (G2/3) sarcomas. 5-year LRFS, DSS and OS for sarcomas aged ≥ 80 vs. < 80 were 72% vs. 90% (P = 0.0048), 57% vs. 79% (P = 0.0079) and 45% vs. 75% (P < 0.0001), respectively. In the cohort of G2/3 (n = 323), Cox analysis with backward elimination method revealed age ≥ 80 as an independent risk factor for poorer LRFS and DSS, with hazard ratio of 2.93 (95% CI: 1.34–6.40) and 2.09 (1.15–3.81), respectively. Conclusions: Despite similar treatment strategy except lower chemotherapy administration, prognosis of G2/3 sarcomas in patients aged ≥ 80 was significantly worse. Characteristic ≥ 80 < 80 Pa n = 36 n = 333 ≤ 5 cm 28% 43% 0.07 Superficial 25% 29% 0.65 G1 0% 14% 0.001* G2 31% 32% G3 69% 54% Inadequate margin 8% 5% 0.50 Adjuvant radiotherapy 89% 87% 0.75 Adjuvant chemotherapy 0% 6% 0.045*